CELCUITY INC. - COMMON STOCK

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

11 Dec 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

14 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

12 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

07 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

14 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

07 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity To Participate in Jefferies Global Healthcare Conference

03 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Celcuity Announces Pricing of Underwritten Common Stock Offering

30 May 2024 07:36:22 By Nasdaq GlobeNewswire

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

30 May 2024 07:00:01 By Nasdaq GlobeNewswire

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

15 May 2024 16:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

08 May 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

04 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

20 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

28 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

22 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

20 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

06 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

01 Dec 2023 11:02:45 By Nasdaq GlobeNewswire